Pliva Generics Company Intelligence Report

Date: October 22, 2009
Pages: 16
Price:
US$ 340.00
License [?]:
Publisher: Espicom Business Intelligence
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: P46A2975D85EN
Leaflet:

Download PDF Leaflet

Pliva Generics Company Intelligence Report
Pliva is based in Croatia, and is one of that country’s leading manufacturing companies. It is also one of the largest pharmaceutical manufacturers in central Europe. It was privatised in the mid 1990s. Total sales amounted to US$1,137 million in 2007, a fall of 9.7% compared with 2006.

Pliva is now owned by the US generic company, Barr Laboratories. Barr bought Pliva for around US$2.5 billion in 2006, after winning a bidding war with Actavis. In April 2007, Barr took direct control of Pliva’s US operations. Pliva will, however, retain its management and independent branding. In late 2008, Barr was in turn acquired by Teva Pharmaceutical Industries.

In March 2008, Barr announced that Pliva would seek to delist from the London Stock Exchange in July 2008. Ordinary shares would continue to be listed on the Zagreb Stock Exchange. Barr cited a lack of liquidity in the firm’s stock following its acquisition.

The company has a broad generic portfolio of prescription, OTC drugs and APIs. It also has one major branded product, azithromycin. Pliva’s US patent for the drug expired at the end of 2005, leading to a slew of generics entering the market. The branded version had been sold for many years in the USA by Pfizer as Zithromax, supplied by Pliva. However, Pliva has now also gained approval for its own generic versions of the drug in the US.

Pliva’s biosimilar development programme has experienced mixed fortunes. In June 2005, the company’s EPO product gained approval from the Croatian Agency for Medicinal Products and Medical Devices. Earlier in 2005, Pliva signed a deal with Mayne Pharma for the commercialisation of biosimilars. However, this was amended in early 2006, and EPO was removed from the agreement following publication of EMEA regulatory guidelines which were more stringent than the companies had anticipated. The company also has a deal with Barr for development of G-CSF.
1.EXECUTIVE SUMMARY

2.INTRODUCTION

3.PRODUCTS

4.FINANCIAL RESULTS

5.MAJOR DEVELOPMENTS

6.CONTACT DETAILS
Skip to top


Ask Your Question

Pliva Generics Company Intelligence Report
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: